← Back to patent-cliff list
CAS 1195768-18-3
methyl 3-amino-2-fluorobenzoate
Codes: DABF-008
Application context (from source-drug indications)
Thyroid cancerDabrafenib MesylateColorectal cancerDabrafenib MesylateGliomaDabrafenib MesylateAnaplastic thyroid cancerDabrafenib MesylateSolid tumourDabrafenib MesylateNon-small cell lung cancerDabrafenib Mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dabrafenib Mesylate | Tier B — Position early | 2029 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2,6-difluorobenzene-1-sulfonyl chloride→2,2-dimethylpropanethioamide→methyl 3-amino-2-fluorobenzoate→methyl 3-(2,6-difluorophenylsulfonamido)-2-fluorobenzoate→2-chloro-4-methylpyrimidine→N-(3-(2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide→N-(3-(2-bromo-2-(2-chloropyrimidin-4-yl)acetyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide→N-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | Methyl 3-amino-2-fluorobenzoate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.